List view / Grid view
GlaxoSmithKline plc and Theravance, Inc. announced that the Japanese Ministry…
4 July 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced that the Japanese Ministry of Health, Labour and Welfare has approved Anoro® Ellipta® (umeclidinium/vilanterol) for the relief of various symptoms due to airway obstruction with chronic obstructive pulmonary diseases...
GlaxoSmithKline plc and Theravance, Inc. announced positive results from two…
11 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced positive results from two phase III studies, which showed that patients with chronic obstructive pulmonary disease who received the anticholinergic, Incruse™ Ellipta®...
GlaxoSmithKline plc presented data at the American Thoracic Society (ATS)…
20 May 2014 | By GlaxoSmithKline
GlaxoSmithKline plc presented data at the American Thoracic Society (ATS) from a late-stage clinical study...
GlaxoSmithKline plc announced that the European Commission has granted marketing…
29 April 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced that the European Commission has granted marketing authorisation for Incruse® (umeclidinium)...
GlaxoSmithKline plc and Theravance, Inc. announced positive results from three…
14 March 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced positive results from three phase III studies...
GlaxoSmithKline plc and Theravance, Inc. announced that recruitment of patients…
14 March 2014 | By GlaxoSmithKline
GlaxoSmithKline plc and Theravance, Inc. announced that recruitment of patients into the “Study to Understand Mortality and MorbidITy”, known as SUMMIT, has completed enrolment...
RELVAR® ELLIPTA® is now licensed across 31 European countries...
18 November 2013 | By GlaxoSmithKline
RELVAR® ELLIPTA® is now licensed across 31 European countries...
GlaxoSmithKline and Theravance announced that the US FDA has approved…
10 May 2013 | By GlaxoSmithKline
GlaxoSmithKline and Theravance announced that the US FDA has approved BREO™ ELLIPTA™...
Results from the pivotal efficacy studies...
2 July 2012 | By GlaxoSmithKline
Results from the pivotal efficacy studies...
GSK and Theravance, Inc. announced the completion of the phase…
9 January 2012 | By GlaxoSmithKline
GSK and Theravance, Inc. announced the completion of the phase III registration programme...
